| |
Predicted risks for future outcomes of incident CKD
|
|---|
|
Moderately increased risk
|
Combined high and very high increased risk
|
|---|
|
Case/number (%)
|
177/2103 (8.4)
|
21/2103 (1.0)
|
|
Each 1-pmol/l increase in FT4
|
|
Model 1
|
1.12 (1.04–1.21)
|
1.18 (1.05–1.34)
|
|
Model 2
|
1.11 (1.03–1.19)
|
1.22 (1.06–1.41)
|
|
Each 1-tertile increase in FT4
|
|
Model 1
|
1.33 (1.09–1.61)
|
2.73 (1.41–5.27)
|
|
Model 2
|
1.30 (1.06–1.59)
|
2.61 (1.32–5.16)
|
- Model 1: adjusted for age, sex, BMI at baseline
- Model 2: further adjusted for triglyceride, HDL-c, diabetes and hypertension status, current smoking and drinking status, use of antihypertensive drugs, use of antidiabetic drugs, urinary ACR, eGFR, TPOAb and TGAb at baseline
- Data are odds ratios (95% confidence intervals), calculated by using multinomial logit regression analysis, referenced to low risk of prognosis of incident CKD
-
ACR albumin-to-creatinine ratio, BMI body mass index, CKD chronic kidney disease, eGFR estimated glomerular filtration rate, FT4 free thyroxine, HDL-c high-density lipoprotein cholesterol, TPOAb thyroid peroxidase antibody, TGAb thyroglobulin antibody
